Abstract: The invention relates to a method for obtaining a visual field map of an observer, particularly a perimetry method, wherein a plurality of test locations in front of the observer is provided, at each test location of a subset of said plurality a respective perceived sensitivity threshold is measured, wherein at least one light signal is provided at the respective test location, and wherein it is monitored whether said observer observes said at least one light signal, and wherein for each test location a respective estimate of the perceived sensitivity threshold is derived from the previously measured perceived sensitivity thresholds of said subset, and wherein said light signal is provided at a light intensity value derived from the estimate of the perceived sensitivity threshold of said respective test location.

Abstract: The invention relates to a modular and stackable system (1) for arranging an optical fibre of an optical system in a controlled and secure manner, comprising at least the following components: a modular frame (30) comprising a plurality of upright posts (31), wherein the posts (31) are arranged such on the frame (30) that a next-neighbour distance of the posts (31) is identical, wherein each post (31) comprises a recess (31a) on the upper end; at least one module (20) for receiving an optical fibre, wherein the module (20) comprises at least four corners (21); wherein the posts (31) are arranged such that four modules (20) can be arranged with their corners (21) non-overlapping on a single post (31); wherein each module's corner (21) can be fixed with a fixing means on the post (31), wherein the fixing means is designed to engage in the recess (31a) on the upper end of the post (31) and wherein the corners (21) of each module (20) and the fixing means are designed such that the fixing means can simultaneously

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: The invention relates to a compound comprising the following general formula (1): and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.

Abstract: The invention relates to a compound wherein R1 is selected from —I, —Br, —Cl, —F, C1-C6-alkyl, —O(CH2)mCH3, —(CH2)mOCH3, C1-C6-haloalkyl, a cycloalkyl, a heterocycle, a aryl or heteroaryl, wherein R2 is selected from H, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, —CH2—(C3-C6-cycloalkyl), or —(CH2)rOCH3, wherein R3 is —NH2, —NH—R4, —NHC(?O)—R4, —NHC(?O)NH—R4, —NHC(?S)—R4 or —NHC(?S)NH—R4, wherein R4 is selected from a cycloalkyl, a heterocycle, a aryl or a heteroaryl, or -L-R5, wherein L is selected from C1-C5-alkyl, a cycloalkyl, a heterocycle, a aryl, or a heteroaryl, and R5 is selected from —OH, —CH2OH, —NH2, —COOH, —CONH2, —CONH—R6 or carboxylic acid isosteres, wherein R6 is selected from C1-C4-alkyl, with n, m and r being 0, 1, 2, 3, 4 or 5 and their use.

Abstract: Provided are tricyclo-DNA (tc-DNA) AON and methods employing tc-DNA AON for modifying splicing events that occur during pre-mRNA processing. Tricyclo-DNA (tc-DNA) AON are described that may be used to facilitate exon skipping or to mask intronic silencer sequences and/or terminal stein-loop sequences during pre-mRNA processing and to target RNase-mediated destruction of processed mRNA.

Abstract: A surgical instrument for treating atrioventricular valve prolapse of the drained human heart, includes a handle for being held by a surgeon, a shaft extending distally from the handle, the shaft having a lumen open to a shaft distal end, a cannulated needle arranged in the shaft; with a distal end of the needle protruding from the shaft distal end at least in one possible needle position. The needle accommodates a first, distal implant equipped for being anchored in a papillary muscle, and a second, proximal implant shaped to hold on to a leaflet of an atrioventricular valve, the first and second implants each including a chord connector portion for connecting the respective implant to an artificial chord. The apparatus further includes a trigger arrangement for releasing the first, distal implant upon a first release actuation and for releasing the second, proximal implant upon a second release actuation.

Abstract: The invention relates to a compound comprising the following general formula (1): and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.

Abstract: The invention relates to a system for estimating the spatial position (pose) of a tool (2) within an object (1), particularly in the form of a human bone that is to be machined with said tool, comprising: a sensor (21) being designed to be coupled to said tool (2), which sensor (21) is further designed to generate an sensor output signal (31) upon machining of said object (1) along an actual trajectory (30), which sensor output signal (31) depends on a material property of said object along said actual trajectory (30), an analyzing means being designed to determine a correlation between said sensor output signal (31) upon machining said object (1) and a plurality of pre-determined candidate output signals (42), each candidate output signal (42) being generated in beforehand using said material property along an associated model trajectory (40) in a model of said object (1), and wherein said analyzing means is designed to estimate a spatial position of the tool (2) within the object (1) using the model traject

Abstract: The invention relates to a peptide dendrimer described by a general formula X—(B2—[Y2]S-D1)2-B1—Z, wherein X is (D2)4 or (D3)8-(B3—[Y3]r-D2)4 or a higher analog, Y is a linkage moiety, Z is a central moiety; each B denotes a diaminoalkylcarboxylic acid moiety; each D is a hydrophobic or cationic amino acid, or a di- or tripeptide composed of hydrophobic and cationic amino acids, for use as a pharmaceutical.

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: The invention relates to a compound comprising the following general formula (1) for use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle or heteroaryl.

Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.

Abstract: The invention relates to a method for determining and particularly imaging sound speed in an object by means of pulse-echo ultrasound, comprising the steps of: transmitting by means of an ultrasound probe (1) at least a first ultrasound pulse (10) in a first direction (?0) and a second ultrasound pulse (20) in a different second direction (?) into an object (O) to be imaged, so that said first ultrasound pulse (10) is backscattered in said object towards said ultrasound probe in the form of first ultrasound pulse echoes (11), and so that said second ultrasound pulse (20) is backscattered in said object towards said ultrasound probe in the form of second ultrasound pulse echoes (21), detecting said backscattered first ultrasound pulse echoes (11) and said backscattered second ultrasound pulse echoes (21) with said ultrasound probe (1), reconstructing from said detected backscattered first ultrasound pulse echoes (11) a first image of first local echoes (5) and from said detected backscattered second ultrasound

Abstract: The invention relates to a compound comprising the following general formula (1): and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.

Abstract: A cutting template for mandibular surgery is described. The cutting template comprises a base; at least two cutting guides for guiding a bone cutting element for cutting a bone, and supported by the base; at least two openings for receiving bone fixation means for fixing the cutting template to the bone; and at least one positioning element for positioning the cutting template against the bone, and comprising a bone mating surface shaped with the contour of the bone against which it is designed to be fitted, and arranged to be in intimate contact with the bone during cutting.

Abstract: Disclosed is a computer-implemented method for modelling human or animal patient tissue. The method includes: acquiring a stressed patient topography data set, the stressed patient topography data set describing a topography of at least one patient tissue surface under mechanical stress; determining an input data set; evaluating a statistic model for the input data set, thereby obtaining an output data set; determining, from the output data set, a relaxed patient topography data set. The statistic model includes a set of Gaussian Processes and is defined by a pre-determined model parameter set, the model parameter set including at least one Gaussian Process parameter for each Gaussian Process, and wherein the statistic model is independent from the patient tissue to be modelled. Disclosed is further a computerized device for carrying out such method. Disclosed are further a computer-implemented method and a computerized device for determining a parameter set.

Abstract: The present invention relates to a system (S) for creating an ablation volume (20) within a target object (1), comprising: an applicator (2) comprising a head (2a), which applicator (2) is configured to be pinserted into the patient's body so as to position said head (2a) into or close to a target object (1) located inside said body, and wherein the applicator (2) is configured to emit energy (E) provided to the applicator (2) via said head (2a) so as to create an ablation volume (20) comprising at least a region of said target object (1), a tracking system (6) configured to track the pose (4) of the head (2a) with respect to the pose (5) of the target object (1), wherein the tracking system (6) is further configured to provide a signal (6a) indicative of the relative pose of the head (2a) of the applicator (2) with respect to the target object (1), and an energy control unit (10) configured to control emission of said energy (E) by the head (2a) of the applicator (2) in response to said signal (6a).

Abstract: A method and system are described for, based upon a plurality of previously-acquired directional LFP signals measured in a plurality of different directions at a directional sensor lead located in a predetermined region of a patient's brain, determining optimised patient-specific programming parameters for programming a directional stimulation lead with parameters for stimulating the said region. The method comprises a first step of determining, over at least one predetermined frequency range, a power-frequency variation curve of each of the directional LFP signals, a second step of identifying frequency peaks in the power-frequency variation curves, a third step of detecting one of the identified frequency peaks at which a maximum difference in signal power between the directional LFP signals occurs, and a fourth step of calculating a plurality of directional stimulation weighting factors on the basis of the relative signal powers of the directional LFP signals at the detected frequency peak.

Abstract: The invention relates to a compound comprising the following general formula (1): and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of R1, R2 and R3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.